Literature DB >> 10431773

Spinocerebellar ataxia type 2 in southern Italy: a clinical and molecular study of 30 families.

A Filla1, G De Michele, L Santoro, O Calabrese, I Castaldo, S Giuffrida, D Restivo, L Serlenga, D F Condorelli, U Bonuccelli, R Scala, G Coppola, G Caruso, S Cocozza.   

Abstract

Autosomal dominant cerebellar ataxia type I is the most common form of dominant ataxia. A genetic heterogeneity has been identified with five different loci (SCA1, 2, 3, 4, and 6). A pathological expansion of a CAG sequence has been identified in SCA1, 2, 3, and 6. We performed molecular analysis in 51 families with autosomal dominant cerebellar ataxia type I, mainly originating from southern Italy and Sicily. Thirty families carry an expanded CAG sequence within SCA2 gene. The mean number of repeats was 39.9 +/- 3.3 in 85 expanded alleles, with a range of 34-52. The number of triplets was inversely correlated with age at onset and explained 76% of the variance. The best fit was obtained with an exponential relationship between variables. Expanded alleles were unstable when transmitted from parents to offspring. Expansions were more common than contractions, accounting for 59% of the total meioses and for 80% of the father-child transmissions. The mean intergenerational variation was 1.9 repeats (range -3 to +15) with higher values for male transmissions. Bulbar and autonomic signs were related to disease duration, pyramidal signs to CAG size, cerebellar features and peripheral neuropathy to both. Among the remaining 21 families, three carried the SCA1 and one the SCA6 mutation. This study suggests that SCA2 is the prevalent mutation in southern Italy.

Entities:  

Mesh:

Year:  1999        PMID: 10431773     DOI: 10.1007/s004150050385

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Therapeutic prospects for spinocerebellar ataxia type 2 and 3.

Authors:  Ilya Bezprozvanny; Thomas Klockgether
Journal:  Drugs Future       Date:  2009-12       Impact factor: 0.148

2.  Early and severe autonomic failure: broadening the clinical phenotype of type-2 spinocerebellar ataxia. A case report.

Authors:  R Capozzo; G Rizzo; M De Mari; C Tortorella; G Logroscino
Journal:  J Neurol       Date:  2014-11-20       Impact factor: 4.849

Review 3.  Disturbed calcium signaling in spinocerebellar ataxias and Alzheimer's disease.

Authors:  Polina Egorova; Elena Popugaeva; Ilya Bezprozvanny
Journal:  Semin Cell Dev Biol       Date:  2015-04-04       Impact factor: 7.727

4.  Jaw-Opening Oromandibular Dystonia Associated With Spinocerebellar Ataxia Type 2.

Authors:  Antonella Antenora; Silvio Peluso; Francesco Saccà; Giuseppe De Michele; Alessandro Filla
Journal:  Mov Disord Clin Pract       Date:  2014-05-26

Review 5.  Deranged calcium signaling in Purkinje cells and pathogenesis in spinocerebellar ataxia 2 (SCA2) and other ataxias.

Authors:  Adebimpe Kasumu; Ilya Bezprozvanny
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

Review 6.  Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.

Authors:  Ilya Bezprozvanny
Journal:  Neurochem Res       Date:  2011-01-06       Impact factor: 3.996

7.  Population based study of late onset cerebellar ataxia in south east Wales.

Authors:  M B Muzaimi; J Thomas; S Palmer-Smith; L Rosser; P S Harper; C M Wiles; D Ravine; N P Robertson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2.

Authors:  Jing Liu; Tie-Shan Tang; Huiping Tu; Omar Nelson; Emily Herndon; Duong P Huynh; Stefan M Pulst; Ilya Bezprozvanny
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

Review 9.  Spinocerebellar ataxia 2 (SCA2).

Authors:  Isabel Lastres-Becker; Udo Rüb; Georg Auburger
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

Review 10.  Intracellular calcium channels: inositol-1,4,5-trisphosphate receptors.

Authors:  Olena A Fedorenko; Elena Popugaeva; Masahiro Enomoto; Peter B Stathopulos; Mitsuhiko Ikura; Ilya Bezprozvanny
Journal:  Eur J Pharmacol       Date:  2013-12-01       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.